In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems
Research output: Contribution to journal › Journal article › peer-review
Standard
In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems. / Heshmati, Nasim; Cheng, Xinlai; Dapat, Else; Sassene, Philip; Eisenbrand, Gerhard; Fricker, Gert; Müllertz, Anette.
In: The Journal of pharmacy and pharmacology, Vol. 66, No. 11, 24.06.2014, p. 1567-75.Research output: Contribution to journal › Journal article › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems
AU - Heshmati, Nasim
AU - Cheng, Xinlai
AU - Dapat, Else
AU - Sassene, Philip
AU - Eisenbrand, Gerhard
AU - Fricker, Gert
AU - Müllertz, Anette
N1 - © 2014 Royal Pharmaceutical Society.
PY - 2014/6/24
Y1 - 2014/6/24
N2 - OBJECTIVES: Anticancer indirubins are poorly soluble in water. Here, digestion of four self-emulsifying drug delivery systems (SEDDS) containing E804 (indirubin-3'-oxime 2,3-dihydroxypropyl ether) was compared by dynamic lipolysis and bioavailability studies. Used lipids were either medium-chain or long-chain glycerides.METHODS: SEDDS E804 were developed. In-vitro lipolysis was carried out at pH 6.5 (37°C) by adding pancreatic lipase (800 U/ml) and controlling by CaCl2 and NaOH addition. E804 content was quantified in the aqueous micellar phase and precipitate using HPLC. Oral bioavailability was determined in rats. Plasma drug content was determined by liquid chromatography (LC)-mass spectrometry.KEY FINDINGS: All formulations reserved E804 in the aqueous micellar phase up to 60 min. Precipitation proceeded towards the end of lipolysis up to 45%. Lowest level of precipitation (21%) occurred with long-chain lipids (LC-SEDDS). However, lipolysis was not really discriminative between formulations as the drug mainly stayed in solution. Oral administration of formulations resulted in similar bioavailability of E804 with no significantly different area under the concentration curve. Only medium-chain self-nanoemulsifying drug delivery systems revealed shorter Tmax compared with the other formulations.CONCLUSION: E804 had a similar performance in four lipid/surfactant systems. All formulations increased the bioavailability of E804 with no significant difference.
AB - OBJECTIVES: Anticancer indirubins are poorly soluble in water. Here, digestion of four self-emulsifying drug delivery systems (SEDDS) containing E804 (indirubin-3'-oxime 2,3-dihydroxypropyl ether) was compared by dynamic lipolysis and bioavailability studies. Used lipids were either medium-chain or long-chain glycerides.METHODS: SEDDS E804 were developed. In-vitro lipolysis was carried out at pH 6.5 (37°C) by adding pancreatic lipase (800 U/ml) and controlling by CaCl2 and NaOH addition. E804 content was quantified in the aqueous micellar phase and precipitate using HPLC. Oral bioavailability was determined in rats. Plasma drug content was determined by liquid chromatography (LC)-mass spectrometry.KEY FINDINGS: All formulations reserved E804 in the aqueous micellar phase up to 60 min. Precipitation proceeded towards the end of lipolysis up to 45%. Lowest level of precipitation (21%) occurred with long-chain lipids (LC-SEDDS). However, lipolysis was not really discriminative between formulations as the drug mainly stayed in solution. Oral administration of formulations resulted in similar bioavailability of E804 with no significantly different area under the concentration curve. Only medium-chain self-nanoemulsifying drug delivery systems revealed shorter Tmax compared with the other formulations.CONCLUSION: E804 had a similar performance in four lipid/surfactant systems. All formulations increased the bioavailability of E804 with no significant difference.
U2 - 10.1111/jphp.12286
DO - 10.1111/jphp.12286
M3 - Journal article
C2 - 24961657
VL - 66
SP - 1567
EP - 1575
JO - Journal of Pharmacy and Pharmacology
JF - Journal of Pharmacy and Pharmacology
SN - 0022-3573
IS - 11
ER -
ID: 120402449